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Abstract
BACKGROUND
Perinatal complications may result in life-long morbidities, among which cerebral
palsy (CP) is the most severe motor disability. Once developed, CP is a non-
progressive disease with a prevalence of 1-2 per 1000 live births in developed
countries. It demands an extensive and multidisciplinary care. Therefore, it is a
challenge for our health system and a burden for patients and their families.
Recently, stem cell therapy emerged as a promising treatment option and raised
hope in patients and their families.
AIM
The aim is to evaluate the efficacy and safety of stem cell treatment in children
with CP using a systematic review and meta-analysis
METHODS
We performed a systematic literature search on PubMed and EMBASE to find
randomized controlled clinical trials (RCT) investigating the effect of stem cell
transplantation in children with CP. After the review, we performed a random-
effects meta-analysis focusing on the change in gross motor function, which was
quantified using the gross motor function measure. We calculated the pooled
standardized mean differences of the 6- and/or 12-mo-outcome by the method of
Cohen. We quantified the heterogeneity using the I-squared measure.
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RESULTS
We identified a total of 8 RCT for a qualitative review. From the initially selected
trials, 5 met the criteria and were included in the meta-analysis. Patients’
population ranged from 0.5 up to 35 years (n = 282). We detected a significant
improvement in the gross motor function with a pooled standard mean
difference of 0.95 (95% confidence interval: 0.13-1.76) favoring the stem cell group
and a high heterogeneity (I2 = 90.1%). Serious adverse events were rare and
equally distributed among both intervention and control groups.
CONCLUSION
Stem cell therapy for CP compared with symptomatic standard care only, shows
a significant positive effect on the gross motor function, although the magnitude
of the improvement is limited. Short-term safety is present and further high-
quality RCTs are needed.
Key words: Cerebral palsy; Perinatal brain injury; Stem cells; Umbilical cord blood;
Mesenchymal stem/stromal cells; Gross motor function; Meta-analysis
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Core tip: Cerebral palsy is a severe motor disability resulting from perinatal
complications. Recently, stem cell therapy emerged as a promising treatment option and
raised hope in patients and their families. However, high-quality randomized clinical
trials investigating the efficacy of stem cell therapy as a treatment for cerebral palsy are
scarce. We included the small number of currently available trials in our meta-analysis.
A slight but significantly positive effect on the gross motor function favoring the stem
cell group can be seen.
Citation: Eggenberger S, Boucard C, Schoeberlein A, Guzman R, Limacher A, Surbek D,
Mueller M. Stem cell treatment and cerebral palsy: Systemic review and meta-analysis. World
J Stem Cells 2019; 11(10): 891-903
URL: https://www.wjgnet.com/1948-0210/full/v11/i10/891.htm
DOI: https://dx.doi.org/10.4252/wjsc.v11.i10.891
INTRODUCTION
Despite advances in perinatal medicine, many infants continue to face serious risks
during pregnancy, parturition, and adaptation after birth. Preterm birth and severe
birth asphyxia are the most frequent complications, which may lead to brain damage
of  the  newborn.  The  clinical  presentation  in  an  individual  child  after  perinatal
complications is complex. This complexity results from multiple potential causal
pathways,  signs  and symptoms of  injury.  Typical  pathology  in  these  newborns
include brain injury and the resulting cerebral palsy (CP). Therefore, CP summarizes
a heterogeneous group of non-progressive disabilities in motor function which range
from slight motor impairment of an isolated body part to the inability of walking or
speaking[1].  Depending  on  the  severity,  typical  symptoms  are  difficulties  in
coordination, stereotypic movement, impossibility of discrete movements, evocation
of primitive reflexes through voluntary movements or co-contraction of agonist and
antagonist  resulting  in  spasticity.  Multiple  other  impairments  such  as  seizure
disorders, altered sensation or perception or musculoskeletal disorders can appear as
additional symptoms[1].  Although the diagnosis of CP does not require cognitive
disability,  about  two-thirds  of  children  with  CP  are  confronted  with  it[2].  Not
surprisingly, CP is the most common motor disability in children with a prevalence of
2  per  1000  live  births  in  developed  countries.  The  prevalence  of  CP  increases
exponentially in preterm infants with decreasing gestational age[3]. For example, the
risk to develop CP is 30 times higher in infants born before 33 wk gestation compared
to term-born infants[3].  Besides  prematurity,  major  risk  factors  include placental
abnormalities, major and minor birth defects, low birthweight, meconium aspiration,
emergency caesarean section, birth asphyxia, neonatal seizures, respiratory distress
syndrome, hypoglycemia, and neonatal infections[4]. Together, CP originates from a
multifactorial pathology with multiple risk factors and in many cases, a distinct cause
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is unclear.
Due to major improvements in neonatal care, half of the children suffering from CP
are preterm infants and the other half are term-born infants[5,6]. This differentiation is
important as prophylactic/therapeutic approaches differ in these two populations.
Currently,  the  only  intervention known to  reduce the  burden of  CP in  the  term
population is hypothermia. Hypothermia is associated with a significant reduction in
death and disability in children subjected to perinatal asphyxia[7]. However, 40%-50%
of infants  treated with hypothermia still  die  or  develop significant  neurological
disability[8].  In  the  preterm  population,  hypothermia  is  contra-productive  and
therapeutic  options  are  lacking.  One  option  is  the  antenatal  magnesium sulfate
prophylaxis at less than 30 wk of gestation, which reduces CP and combined CP and
mortality  rate  at  2-years  of  age.  However,  long-term  neurological  benefits  are
lacking[9,10].  New  avenues  to  treat  CP  emerged  and  stem  cell  treatments  are
particularly promising. We review the potential of a stem cell transplant using a meta-
analysis to evaluate gross motor function after randomized controlled trials (RCTs) in
children with CP.
Which source of stem cells to use?
Stem  cells  are  characterized  as  cells  with  the  capacity  of  self-renewal  and
differentiation into multiple tissues[11]. Their program of division and differentiation is
regulated by the immediate microenvironment, also called the niche. Stem cells are
grouped depending on the number of tissues they can differentiate into[12]. Totipotent
cells can differentiate into any cell type found in an organism. They exist for a very
limited time only in the embryo shortly after fertilization. Pluripotent cells are the
next stage; they occur in the blastocyst and can form cells from each of the three
germinal  sheets.  Multipotent  stem  cells  can  also  be  detected  in  adults.  Their
differentiation  capability  is  restricted  to  cell  types  within  one  germinal  sheet.
Unipotent stem cells are responsible for the renewal of a single tissue lineage. In vitro,
apart from their self-renewal and differentiation capacity, stem cells can be identified
by  markers,  which  are  gene  products  expressed  by  specific  types  of  stem cells.
Therefore, by means of flow cytometry, stem cells can be identified and quantified[11].
Embryonic  or  pluripotent  stem  cells  seem  to  be  very  promising  due  to  their
differentiation ability[11]. However, their unlimited self-renewal and differentiation
capacity  combined  with  a  lack  of  cell-cell-interaction  and  regulation  through
extraembryonic cells may lead to tumor formation[13]. Additionally, the harvesting of
pluripotent cells results in the death of the embryo raising major ethical concerns.
Therefore,  the main stem cell  sources in CP treatment are bone marrow (BM) or
umbilical cord blood (UCB)-derived stem cells.
Umbilical cord blood and bone marrow as a source of stem cells
UCB is a rich source of stem cells. It can be collected after birth and stored in public or
private  banks  for  a  possible  future  use[14].  It  contains  several  types  of  stem and
progenitor  cells,  among  which  hematopoietic  stem  cells  (HSC),  mesenchymal
stem/stromal  cells  (MSC)  and  endothelial  progenitor  cells  (EPC)  are  the  most
relevant.  Further,  the  existence  of  embryonic-like  stem  cells  is  controversially
discussed. Besides the simple isolation without ethical concerns, these cells have a
remarkably low immunogenicity. Compared to stem cells from other sources, UCB
cells tolerate more human leukocyte antigen (HLA)-mismatches without rejection[12].
The reason for this might be the immature fetal immune system. Today, cord blood is
routinely used to treat hematopoietic or immunologic disorders[15]. In the last years,
promising trials have shown that UCB stem cells have great potential in the treatment
of various neurological diseases[16].  A world-wide network of cord blood banks is
available  for  unrelated  cord  blood  transplantations.  For  therapeutic  use,  the
mononuclear fraction is isolated from cord blood by means of a density gradient[17].
The mononuclear fraction includes immunosuppressive cells such as regulatory T-
cells  and  monocyte-derived  suppressor  cells[16].  Each  of  these  cell  types  has
characteristics  that  are  likely  to  contribute  to  neuroprotection.  Notably,  the
composition of those cells depends on the timing of sampling (gestational age of
pregnancy)[18]. For example, UCB derived from preterm placentae is different in its
mononuclear  fraction  from  term-derived,  and  UCB  from  intrauterine  growth
restriction infants has impaired EPC[19].
BM is the major hematopoietic organ localized in the central cavities of axial and
long  bones[20].  Differentiation  and  proliferation  of  the  blood  cells  occur  in  the
hematopoietic  compartment.  It  is  composed  of  HSC  and  the  precursors  for  the
different blood lineages. It used to be the main source of HSC for clinical use, until
recently less invasive techniques allowed to obtain HSC from other sources such as
granulocyte-colony  stimulating  factor-stimulated  peripheral  blood  or  UCB[21].
Importantly, the stroma is responsible for the regulation of the hematopoietic process
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and  contains  MSC  and  EPC  along  with  their  products  of  differentiation  like
fibroblasts and endothelial cells. Compared to UCB, MSC are more frequent in BM.
Although BM harvesting requires an invasive procedure, BM is still the main source
for MSC[22]. Notably, the number of both EPC and MSC in BM decline with age[20,23].
Mesenchymal stem/stromal cells
MSC are a heterogeneous population of multipotent cells that can differentiate into
bone  (osteoblasts),  fat  (adipocytes),  cartilage  (chondroblasts)  and  periosteum
(fibroblasts)[24]. Their differentiation potential into the neurogenic direction is debated,
but the discussion remains controversial[17]. Originally, MSCs were discovered in BM
as part of the mononuclear cell fraction, where they support HSC[25]. Meanwhile, they
have  been  isolated  from  many  other  sources  including  adipose  tissue,  muscle,
placental tissues,  and UCB. The International Society for Cell  and Gene Therapy
elaborated minimal criteria to define MSCs[26]. It remains unclear and much discussed
what MSC’s function in each source is. Some even consider the pericyte to be the cell
of origin of MSC in vivo. Thus, their function could be the regulation of the capillary
blood flow and permeability[27]. There are high expectations for MSC as a therapy in
various diseases.  A special  interest  lies in the treatment of  neurological  diseases
including CP[24]. Also, MSC have become more and more commercialized as source of
replacement for damaged structures. However, injected allogeneic MSC are rejected
by the host immune system and likely to be eliminated soon after the transplantation
and in contrast, autologous ones may persist for some longer time[27]. Not surprisingly,
the therapeutic effect of MSC is attributed not to the differentiation capacity and thus
formation of new tissue, but to the secretome, which contains modulatory factors[28].
These  modulate  oxidative  stress  and  has  angiogenetic,  anti-apoptotic  and  anti-
inflammatory effects[28]. MSC have different characteristics depending on their origin.
Of special interest are those MSC derived from fetal tissues such as UCB, placental or
cord  tissues,  which  are  believed  to  have  a  wider  differentiation  and  greater
proliferation potential[29,30].  Moreover,  they can easily be isolated non-invasively,
rapidly and without ethical concern nor invasive procedures[31]. However, we are not
always successful to isolate a sufficient number of MSC from UCB for clinical use[32].
Hematopoietic stem cells and endothelial progenitor cells
Both HSC and EPC can be found in BM as well  as in UCB. HSC are multipotent
precursor cells with the ability to form all blood cells while maintaining a sufficient
HSC-pool to provide hematopoiesis throughout life[33]. Whilst HSC transplantation
was the first established stem cell transplantation and exclusively for hematologic
disorders,  HSC  now  also  become  interesting  in  the  field  of  non-hematologic
diseases[34].  Of special interest for a possible neuroprotective contribution is their
beneficial effect in ischemic brain injury in animal models[35]. EPC too are believed to
possess  neuroprotective  features.  Apart  from  their  ability  to  differentiate  into
endothelial cells, they are believed to induce neovascularization and reduce hypoxia-
induced apoptosis and destruction of blood vessels[36,37]. Considering these in-vitro
characteristics  of  both  HSC  and  EPC,  they  may  play  a  role  in  neuroprotective
therapies such as the treatment of CP as well.
MATERIALS AND METHODS
Literature search
We followed the PRISMA-statement guidelines to perform a systematic electronic
search using PubMed and EMBASE databases for trials published between January 1,
1990, and February 11, 2019. To be eligible for inclusion, the trial was required to be a
randomized, controlled clinical trial with full-text availability in English. Further, the
study population  must  consist  of  children  diagnosed  with  any  type  of  CP.  The
intervention must  include any kind of  stem cell  treatment  compared to  placebo
and/or  standard  of  care  such  as  rehabilitation.  The  motor  outcome  of  both
intervention and control group must be assessed and reported in the Gross Motor
Function Measure (GMFM). We excluded trials that did not meet these criteria from
the analysis.
We combined terms like “stem cells”, “neural progenitor cells”, “mesenchymal
stem cells” or “umbilical cord blood” to match the intervention with “cerebral palsy”
in both databases. We set the limitations to human-controlled clinical trials in English
only. Also, we detected trials from bibliographies of other articles. We identified the
potentially relevant articles through title and abstract screening and proceeded to the
definite inclusion or exclusion according to their content (supplementary materials).
The study selection process is illustrated in Figure 1.
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Figure 1
Figure 1  Study selection process.
Meta-analysis
We defined the efficacy of stem cell therapy as a change in gross motor function. To
summarize the gross motor outcome from the intervention group compared to the
control group, we performed a random-effects meta-analysis using the method of
DerSimonian  et  al[38].  We  pooled  the  standardized  mean  differences  and  the
heterogeneity was quantified using the I-squared measure, taken from the inverse-
variance fixed-effect model. All analyses were done in Stata version 15 using the
command meta version 3.04.
RESULTS
Study selection and characteristics
After applying the inclusion and exclusion criteria, we identified 8 relevant trials for
further analysis (Figure 1). Four of them have been conducted in China, three in Korea
and one in the United States of America. Publication dates ranged from 2012 to 2018.
The study characteristics are summarized in Table 1. Five trials investigated stem cell
therapy  plus  rehabilitation  to  rehabilitation  only,  one  trial  compared  stem  cell
therapy. only to rehabilitation and two trials compared stem cell therapy only to no
intervention in the control group. Two of the included studies were three-group
randomized clinical trials investigating the additive effect of erythropoietin[39] or using
mononuclear cells[40].  Two other studies were designed as randomized controlled
crossover-trials[41,42]. The age in the study population ranged from 6 mo to 35 years. All
patients included were diagnosed with CP. The severity of CP was measured with the
Gross Motor Function Classification System, which divides the syndrome of CP into 5
levels, whereof level 5 is the most severe motor impairment[43]. The type and dose of
the stem cells differed in the trials. One trial used neural progenitor cells derived from
aborted fetuses’ forebrains[44], while others included umbilical cord- or BM-derived
stem cells[39,41,45-47]. The applied dose ranged from 4 × 106 to 6 × 108 cells. The number of
cells was not always adapted to body weight. The application route was in most cases
the intravenous route. In summary, both the study population and the intervention
characteristics are heterogeneous, which leads to a certain risk of bias summarized in
Table 2 and Figure 2.
Risk of bias
We assessed the risk of bias in individual studies using the Cochrane criteria. The risk
ranged from low to high. The major source of risk of bias was patient and personnel
blinding[40,44-46].  The  number  of  trials  was  not  sufficient  to  estimate  the  risk  for
publication bias.
Outcome measurements
All included trials applied standardized scales to assess the neurodevelopmental
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Table 1  Intervention and study population overview
Study Population Intervention
Ref. Country Samplesize Age (yr)
Patient
condition
Interventi
on and
study
groups
Applicati-
on route
Type of
stem cells Source Origin Dose
Chen et
al[45], 2013
China 60 1-35 CP,
GMFCS
level 3 to 5
Group 1:
SC +
rehabilita-
tion Group
2:
Rehabilita-
tion only
Intrathecal Mesenchy-
mal stem
cells in vitro
transfor-
med to
neural
stem cell-
like cells
Bone
marrow
Autolog-
ous
Fixed
quantity of
1-2 × 107
cells, twice
Huang et
al[46], 2018
China 56 3-12 CP Group 1:
SC +
rehabilita-
tion Group
2: Placebo
+
rehabilita-
tion
Intrave-
nous
Mesenchy-
mal stem
cells
Cord blood Allogeneic Fixed
quantity of
5 × 107
cells, 4
times
Kang et
al[47], 2015
South
Korea
36 0.5-20 CP,
GMFCS
level 1 to 5
Group 1:
SC Group
2: Placebo
No
rehabilita-
tion
Intrave-
nous/intra-
arterial
Mononucl-
ear cells
Cord blood Allogeneic1 5.46 × 107
cells/kg,
once
Liu et
al[40], 2017
China 105 0.5-12.5 Spastic CP,
GMFCS
level 2 to 5
Group 1:
MNC
Group 2:
MSC
Group 3:
rehabilita-
tion
Intrathecal Mesenchy-
mal
stromal
cells and
mononucl-
ear cells
Bone
marrow
Autolog-
ous
106
cells/kg, 4
times
Luan et
al[44], 2012
China 91 < 0.5-3.5 CP,
GMFSC
level 1 to 5
Group 1:
SC +
rehabilita-
tion Group
2:
rehabilita-
tion only
Intraventri-
cular
Neural
progenitor
cells
Aborted
healthy
fetuses’
forebrains
Allogeneic Fixed
quantity of
8-10 × 106
cells, once
Min et
al[39], 2013
South
Korea
105 0.8-10 CP Group 1:
SC+ EPO +
rehabilita-
tion Group
2: placebo
SC + EPO +
rehabilita-
tion Group
3: placebo
SC+
placebo +
rehabilita-
tion
Intrave-
nous
Mononucl-
ear cells
Cord blood Allogeneic1 ≥ 3 × 107
cells/kg,
once
Rah et
al[42], 2017
South
Korea
57 2-10 Non-severe
CP
Group 1:
G-CSF at
baseline,
SC 1 mo
later Group
2: G-CSF at
baseline,
placebo 1
mo later
crossover
at 7 mo
Intrave-
nous
Mobilized
mononucl-
ear cells
Peripheral
blood
Autolog-
ous
5.97 × 108
cells/ kg,
once
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Sun et
al[41], 2017
USA 63 1-6 CP of any
type,
GMFCS
Level 2 to 4
or 1 with
hemiplegia
Group 1:
SC +
rehabilita-
tion Group
2: Placebo
+
rehabilita-
tion
Intrave-
nous
Mononucl-
ear cells
Cord blood Autolog-
ous
2 × 107
cells/kg,
once
1Administation of cyclosporine. MNC: Mononuclear cells; MSC: Mesenchymal stem cells; EPO: Erythropoietin; CP: Cerebral palsy; SC: Stem cells; GMFCS:
Gross motor function classification system.
outcome. The fine and gross motor function, cognitive function and spasticity were
measured. In the following analysis, we focused on the gross motor function outcome
only. The gross motor function was evaluated with the GMFM-66 or GMFM-88[43].
Both scores categorize 5 sections: Lying, Sitting, Crawling, Standing and Walking.
Each of these categories is expressed in the percentage of the maximum achievable
points. To determine the total score, the percentages of all categories are added up
and divided by  five  and therefore  expresses  the  average  score  of  all  categories.
Importantly, the total score varies depending on the severity of CP and the patient’s
age. The observation period in the included trials was 6 months in three trials, 12 mo
in another three and 24 in the remaining two trials (see Table 3 for details). Functional
assessments  to  measure  the  outcomes  were  performed  at  baseline,  after  the
observation period, and additionally at one to three points in-between. Most GMFM
data were available for the 6- and 12-mo periods and therefore we decided to proceed
with those for the meta-analysis.
Cell dose, gross motor function and safety
Three trials  from the initial  literature  search had to  be excluded from the meta-
analysis due to the lack of GMFM scores in an averaged format[45], missing standard
deviation or standard error in the GMFM scale[42], or no comparable outcome score of
the control group given[44]. One study did not provide changes in GMFM summary
scores from baseline, but only absolute GMFM dimension scores at baseline, 6 months
and 12 mo[40]. Therefore, we averaged the dimension scores and their variations and
calculated the changes from the baseline. The cell dose used in the included trials
differed but improved motor outcome seems to correlate with a higher cell dose[41,42,47]
(Tables 1 and 3). We generated a forest plot with the available GMFM-scores at 6 and
12 mo (see Figures 3-5). Additionally, we pooled all studies; the resulting forest plot is
presented in Figure 5. Besides the improvement of gross motor function, the studies
assessed the serious adverse  events  (SAE).  Overall,  only two trials  reported the
occurrence of SAEs[39,44] (Table 4). One case of hemorrhagic foci after transplantation
was detected and was presumably linked to the invasive procedure[44]. The other SAEs
mainly consisted of infections or seizures[39]. These SAEs were equally distributed
between both cell recipient and control groups. There is no report of an overdose in
any of the included trials. The highest dose applied was a mean dose of 5.97 × 108
cells/kg and no SAEs were reported[42]. Together, the included RCTs provide short-
term safety, whereas the long-term impact is unclear.
DISCUSSION
Using a systematic literature review, we identified 8 RCTs investigating the effect of
stem cell treatment in children with CP vs  standard care with or without placebo.
Based on our inclusion criteria, we included 5 trials in the meta-analysis with a total of
282 patients (142 control, 140 cell recipient group). By combining the outcome, we
identified a significant improvement in the cell recipient compared to the control
group (Figure 5). The pooled standard mean difference was 0.95 (95% confidence
interval: 0.13-1.76). However, we detected a high heterogeneity (I2 = 90.1%), which
reflects  the  diverse  patient  characteristics  and  needs  to  be  accounted  for  while
discussing the results. Besides, our analysis only includes the results from 5 trials,
which  is  hardly  enough  to  represent  the  whole  CP  population.  A  search  on
clinicaltrials.gov identified 9  ongoing randomized clinical  trials  about  stem cell
therapy in CP. Therefore, evidence might grow stronger in the future with greater
data acquisition.
In  the  included  trials,  the  origin  (autologous  or  allogeneic),  type  (MSC,
mononuclear cells, and neural progenitor cells), and source (BM, brain tissue, UCB) of
the transplanted cells differed. Interestingly, in patients receiving the transplant with
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Table 2  Evaluation of the risk of bias
Ref.
Random
sequence
generation:
Selection bias
Allocation
concealment
Blinding of
participants and
personnel:
Performance bias
Blinding of
outcome
assessment:
Detection bias
Incomplete
outcome data:
Attrition bias
Selective
reporting
Chen et al[45], 2013 High High High Low High High
Huang et al[46], 2018 Unclear Unclear High Low Low Unclear
Kang et al[47], 2015 Low Low Low Low Low Unclear
Liu et al[40], 2017 Low Unclear High Unclear Low Low
Luan et al[44], 2012 Unclear Unclear High Unclear High Unclear
Min et al[39], 2013 Low Low Low Low Low Low
Rah et al[42], 2017 Low Low Low Low High Unclear
Sun et al[41], 2017 Low Low Low Low Low Unclear
fewer  HLA-mismatches,  the  improvement  of  gross  motor  function  was  clearly
evident[39,47]. We speculate that autologous cells may show a greater benefit in motor
function  improvement.  Furthermore,  the  matching  of  HLA  seems  to  have  less
relevance in case of a MSC transplant[46]. For example, both studies with a significant
increase in the motor outcome used a MSC transplant[40,46]. These observations are
further supported by the direct comparison of mononuclear fraction of BM stem cells
and MSC alone[40], which clearly favors a MSC alone approach. Together, the present
studies  suggest  that  MSC are  the  ideal  candidates  to  modulate  the  gross  motor
function in CP. The source may be the UCB as it is less invasive and easily accessible.
However, harvesting a sufficient number of cells can only be achieved in around 40%
of the samples[48],  which limits the use of autologous UCB-derived MSC. Further
studies  are  warranted  especially  as  other  easily  available  MSC sources  such  as
Wharton`s jelly of the umbilical cord are very promising[49,50].
In order to report a proper gross motor function improvement, both the patient’s
age and level of motor impairment need to be considered by using percentiles[51].
However, only one of the included trials used proper percentiles and presented the
results as “greater than expected”[41].  Interestingly, this trial detected a significant
gross motor function improvement using a higher cell  dose (≥ 2 × 107  cells) only.
Another consideration is the use of repeated cell  applications[40,46].  Given that the
pathophysiology of CP consists of persistent inflammation, such repetitive doses
would be plausible[52]. Moreover, the transplanted cells do not persist for a very long
time[53], which further supports concurrent use. Eventually, the included trials do not
clearly provide a specific effective dose of cells, but it should be more than 2 × 107
total nucleated cells and may go up to 6 × 108 without the risk of overdosing[41,42]. The
invasive transplantation routes such as the lumbar puncture were chosen to bypass
the blood-brain barrier but resulted in a higher number of reactions like nausea and
headache[40].  However, the modulation of inflammatory responses by secretion of
factors can be achieved peripherally[54], making the route of application less relevant
for the efficacy of the cells[55].
In conclusion, stem cell therapy for CP compared with symptomatic standard care
only, shows a significant positive effect on the gross motor function, although the
magnitude of the improvement is limited. Especially MSC show a positive outcome.
This novel treatment seems safe, at least in the short term. However, high-quality
RCTs are still lacking.
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Table 3  Raw motor outcome data
Ref. Follow-up assessmentsafter intervention (mo)
Change in GMFM-88/66
after 6 mo ± SD
Change in GMFM-88/66
after 12 mo ± SD
% improvement compared
to baseline after whole
observation period
Chen et al[45], 2013 1, 3, 6 Numbers inaccurately
indicated
- -
Huang et al[46], 2018 3, 6, 12, 24 Control: + 2.96 ± 1.66; MSC: +
7.62 ± 2.44
Control: + 4.75 ± 1.45; MSC: +
10.27 ± 2.96
Control: 5.67%; UCB: 14.89%
Kang et al[47], 2015 1, 3, 6 Control: 3.85 ± 3.75; UCB: 7.08
± 7.36
Control: 13.1%; UCB: 24.2%
Liu et al[40], 2017 3,6, 12 Control: + 1.85; BMMNC: +
3.1; BMMSC: + 10.45
Control: + 2.91; BMMNC: +
6.46; BMMSC: + 12.52
Control: 7.84%; BMMSC:
33.76%
Luan et al[44], 2012 1, 6, 12 Control: not indicated; NPC: +
8.86
- -
Min et al[39], 2013 1, 3, 6 Control: + 7.8 ± 5.1; EPO only:
+ 9.0 ± 6,3; UCB + EPO: + 9.1
± 6.7
- No baseline score provided
Rah et al[42], 2017 12 mo after treatment resp. 6
mo for crossover-group
- Transplantation at baseline: +
2.9; Transplantation after 6
mo: + 6.37
No baseline score provided
Sun et al[41], 2017 12, 24 - Control: + 6.9 ± 5.5; UCB: +
7.5 ± 6.8 (High dose:
improvement + 4.3 ± 1.5
greater than expected. Low-
dose and placebo: no
significant improvement
beyond expectation.)
Control: 13.3%; UCB: 15.3%
BMMNC: Bone marrow mononuclear cells; BMMSC: Bone marrow mesenchymal stem cells; EPO: Erythropoietin; NPC: Neural progenitor cells; UCB:
Umbilical cord blood; MSC: Mesenchymal stem cells; GMFM: Gross Motor Function Measure.
Table 4  Reported serious adverse events
Ref. Serious adverse events incell recipient group
Serious adverse events in
control group Allogenic cells Application route
Chen et al[45], 2013 0/30 0/30 Intrathecal
Huang et al[46], 2018 0/27 0/27 x Intravenous
Kang et al[47], 2015 0/18 0/18 x (+ immunosuppressant) Intravenous/intraarterial
Liu et al[40], 2017 0/68 0/34 Intrathecal
Luan et al[44], 2012 1/45 0/49 x Intraventricular
Min et al[39], 2013 3/36 6/70 x (+ immunosuppressant) Intravenous
Rah et al[42], 2017 0/57 - Intravenous
Sun et al[41], 2017 0/63 - Intravenous
Total 4/344 (1.2%) 6/228 (2.6%)
Figure 2
Figure 2  Overall risk of bias.
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Figure 3
Figure 3  Forest plot showing the effect size of the change in the Gross Motor Function Measure in the intervention group compared to the control group
after 6 mo. GMFM: Gross Motor Function Measure; SMD: Standard mean difference; CI: Confidence interval.
Figure 4
Figure 4  Forest plot showing the effect size of the change in the Gross Motor Function Measure in the intervention group compared to the control group
after 12 mo. GMFM: Gross Motor Function Measure; SMD: Standard mean difference; CI: Confidence interval.
Figure 5
Figure 5  Forest plot showing the effect size of the change in the Gross Motor Function Measure in the intervention group compared to the control group. If
available, measures at 12 mo were used[40,41,46], else, measures at 6 mo were used[39,47]. GMFM: Gross Motor Function Measure; SMD: Standard mean difference;
CI: Confidence interval.
ARTICLE HIGHLIGHTS
Research background
Cerebral  palsy  (CP)  is  a  severe,  uncurable  motor  disability  resulting  from  perinatal
complications. It is a challenge for our health system and a burden for both patients and their
families.
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Research motivation
During the last years, stem cell therapy emerged as a novel treatment option. Clinical trials
report promising results and create high expectations. However, most trials are of poor quality
and neither randomized nor controlled, so the scientific evidence remains doubtful.
Research objectives
The aim of our meta-analysis was to investigate the effect of stem cell treatment on the gross
motor function in children with CP.
Research methods
With  a  systematic  literature  search  on  PubMed  and  EMBASE,  we  identified  the  eligible
randomized controlled clinical trials (RCTs). We performed a random-effects meta-analysis
focusing on the change in gross motor function and calculated the pooled standardized mean
differences of the 6- and/or 12-mo-outcome.
Research results
We identified a total of 8 RCTs for a qualitative review. From the initially selected trials, 5 met
the criteria and were included in the meta-analysis. Patients’ population ranged from 0.5 up to 35
years (n = 282). We detected a significant improvement in the gross motor function with a pooled
standard mean difference of 0.95 (95% confidence interval: 0.13-1.76) favoring the stem cell
group and a high heterogeneity (I2  = 90.1%). Serious adverse events were rare and equally
distributed among both intervention and control groups.
Research conclusions
Stem cell therapy for CP compared with symptomatic standard care only, shows a significant
positive effect on the gross motor function, although the magnitude of the improvement is
limited.
Research perspectives
Considering that this small number may not be enough to represent the whole CP population,
our meta-analysis detected a small but significant improvement in the gross motor function
favoring the stem cell group. However, the magnitude of the effect is limited. In the future, high-
quality research with a more homogenous study population is needed to bring more clarity.
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